Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

Journal of Clinical Pharmacology

Volumn 54, Issue 10, 2014, Pages 1097-1107

  Chen, Nianhang ^a   Li, Yan ^a   Ye, Ying ^a   Palmisano, Maria ^a   Chopra, Rajesh ^a   Zhou, Simon ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

covariates; nab paclitaxel; neutropenia; pharmacodynamics; pharmacokinetics

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; PACLITAXEL; SOLVENT; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY SIZE; CANCER CHEMOTHERAPY; CANCER PATIENT; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MODERATE HEPATIC IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL; NONLINEAR SYSTEM; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA; SEVERE HEPATIC IMPAIRMENT; SOLID TUMOR; TUMOR CLASSIFICATION; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; CHEMICALLY INDUCED; DOSE RESPONSE; LIVER DISEASE; META ANALYSIS; NEOPLASMS; PATHOPHYSIOLOGY; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; NONLINEAR DYNAMICS; PACLITAXEL; YOUNG ADULT;

EID: 84921938116     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.304     Document Type: Article

References (31)

1. Abraxane [package insert]. Summit, NJ: Celgene Corporation; 2013.
2. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006; 12 (4): 1317-1324.
3. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23 (31): 7794-7803.
4. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30 (17): 2055-2062.
5. Von Hoff DD, Ervin TJ, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369 (18): 1691-1703.
6. Taxol [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2011.
7. Taxotere [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2013.
8. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002; 8 (5): 1038-1044.
9. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV,. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994; 12 (3): 532-538.
10. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995; 13 (1): 180-190.
11. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH,. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999; 81 (2): 330-335.
12. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH,. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996; 56 (9): 2112-2115.
13. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999; 59 (7): 1454-1457.
14. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008; 14 (13): 4200-4205.
15. Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH,. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res. 2006; 12 (7 pt 1): 2150-2157.
16. Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res. 2007; 13 (21): 6410-6418.
17. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO,. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002; 20 (24): 4713-4721.
18. Henningsson A, Karlsson MO, Viganò L, Gianni L, Verweij J, Sparreboom A,. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol. 2001; 19 (20): 4065-4073.
19. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993; 11 (11): 2127-2135.
20. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol. 1995; 6 (7): 699-704.
21. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994; 12 (8): 1621-1629.
22. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005; 23 (31): 7785-7793.
23. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005; 11 (11): 4136-4143.
24. Biakhov MY, Kononova GV, Iglesias J, et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf. 2010; 9 (4): 515-523.
25. Guan Z, Li QL, Feng F, et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. Asia Pac. Asia Pac J Clin Oncol. 2009; 5 (3): 165-174.
26. Hersh EM, Del Vecchio M, Brown MP, et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel vs dacarbazine in previously untreated patients with metastatic malignant melanoma. Pigment Cell Melanoma Res. 2012; 25 (6): 863.
27. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012; 18 (10): 2954-2963.
28. Lyman GH, Lyman CH, Agboola O,. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10 (6): 427-437.
29. Kearns CM, Gianni L, Egorin MJ,. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol. 1995; 22 (3 suppl 6): 16-23.
30. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009; 27 (22): 3611-3619.
31. Joerger M, Huitema AD, Huizing MT, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2007; 64 (5): 622-633.